Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare

Jiangsu Vcare’s Second-Generation Selective JAK1 Inhibitor VC005 Completes Phase II Enrollment for Ankylosing Spondylitis

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of Phase II clinical enrollment for its self-developed second-generation selective JAK1 inhibitor VC005 tablets in the treatment of ankylosing spondylitis (AS). Preliminary blinded analysis from the clinical trial demonstrated favorable efficacy and safety profiles for VC005.

View Details

Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Completes First Patient Enrollment in China's Pivotal Phase II Trial

Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) completed the first patient enrollment in the pivotal Phase II clinical trial (Registration Number: CTR20201703) in China for its self-developed next-generation TRK inhibitor, VC004. This clinical trial aims to further evaluate the efficacy and safety of VC004 in treating patients with NTRK gene fusion mutations.

View Details

Jiangsu Vcare Submitted an NDA for Anti- platelet Drug Vicagrel to the US

Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) submitted an NDA to the US FDA for Vicagrel capsules for the treatment of acute coronary syndrome (ACS), ischemic stroke, and confirmed peripheral arterial disease. This marks the first NDA submission from Jiangsu Vcare's innovative drug pipeline, representing a significant milestone.

View Details

Jiangsu Vcare Secures Over CNY 450 Million in Series C Funding

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C financing round, raising over CNY 450 million. The investment consortium included China Life Private Equity Investment, DYEE Capital, Hongyao Technology Capital, existing investor Nanjing Innovation Capital Group, and Hangzhou Huadian Investment.

View Details

Jiangsu Vcare Approved to Establish "Provincial-Level Enterprise Technology Center"

Recently, the Jiangsu Provincial Department of Industry and Information Technology released the list of enterprises proposed for recognition as 2023 Provincial-Level Enterprise Technology Centers. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) has been recognized as a"2023 Provincial-Level Enterprise Technology Center".

View Details

Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Enters Pivotal Phase II Trial

Recently, the initiation of the pivotal Phase II trial for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 project was announced at its first center, the Cancer Hospital Chinese Academy of Medical Sciences. Subsequent recruitment will take place across nearly 30 clinical centers nationwide.

View Details